Skip to main navigation

Skip to content

Return to T2 Biosystems Homepage Contact T2 Biosystems

Investor Relations

Overview
Corporate Governance
Press Releases
SEC Filings
Events & Presentations
Annual Reports
Investor FAQ
Stock Information
Email Alerts

Tools

Print Page
RSS Feeds
Email Alerts

Event Details

Third Quarter 2022 Results Conference Call

Thursday, November 10, 2022 4:30 pm EST

Click here for webcast

Unauthorized recording or downloading of this event is not permitted.

T2 Biosystems OVERVIEW

T2 Biosystems, an emerging leader in the field of in vitro diagnostics, is dedicated to saving lives and reducing the cost of healthcare by empowering clinicians to effectively treat patients faster than ever before. T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most expensive conditions in hospitals today.

The T2Dx Instrument and T2Candida Panel have received marketing authorization from the U.S. Food and Drug Administration. All other T2 Biosystems products are considered investigational and for research use only.

T2 Biosystems®, T2MR®, T2Candida®, T2Dx®, and T2 Bio® are registered trademarks of T2 Biosystems, Inc. T2HemoStat™, T2Plex™, and T2Bacteria™ are trademarks of T2 Biosystems, Inc.

© 2024 T2 Biosystems, Inc.

JOIN IN ON TWITTER

Sitemap

T2Direct Diagnostics
T2MR Technology
Pipeline
Our Company
Terms of Use & Privacy Policy
Conflict Mineral Report

Investors
T2Blog
Technical Support
Careers
Contact Us
Standard Terms & Conditions

Follow Us on Social

LinkedIn
Twitter